Healthcare
Angiex, Inc. – SUCCESS PAGE – January 28, 2025
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Ceresti’s Caregiver-Enabled Dementia Program is a tech-powered approach to dementia care that reduces the total cost of care by more than 30%
Ceresti’s Caregiver-Enabled Dementia Program is a tech-powered approach to dementia care that reduces the total cost of care by more than 30%
ZYUS Life Sciences (CVE: ZYUS) is creating a world where chronic pain is managed effectively without opioids.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
ZYUS Life Sciences (CVE: ZYUS) is creating a world where chronic pain is managed effectively without opioids.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
A clinical-stage precision medicine company enhancing patient outcomes through improved decision-making and personalized cancer care.
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease